This bill amends the Social Security Act to add multi-cancer early detection screening tests to the list of items and services that may be covered by Medicare. It defines the tests, requires CMS to use the national coverage determination process to make coverage decisions, sets an interim payment benchmark and a post‑2029 transition rule, and creates age and frequency limits on payment.
Why it matters: the measure creates an explicit statutory reimbursement route for a class of emerging screening technologies (chiefly blood-based tests that analyze cell-free nucleic acids). That changes the commercial calculus for test developers, clinical labs, and health systems — while raising implementation and evidence-review questions for CMS, providers, and Medicare finances.
At a Glance
What It Does
Adds a statutory definition for 'multi-cancer early detection screening tests' and requires the Secretary to apply the Medicare national coverage determination (NCD) process when deciding coverage. It sets an interim payment equal to the rate for multi-target stool DNA tests through 2030 and then caps future payment by reference to the payment rules under section 1834A beginning January 1, 2031. The bill also imposes an annual-use restriction (no payment within 11 months of a prior test) and a rolling age cutoff that begins at 68 in 2028 and increases by one year each calendar year.
Who It Affects
Medicare fee-for-service beneficiaries who would be eligible for these tests, developers and manufacturers of genomic or blood‑based cancer screening assays, clinical laboratories that would perform and bill for the tests, CMS and Medicare administrative contractors implementing coverage and payment, and oncology/diagnostic providers managing follow-up care.
Why It Matters
This is the first federal statutory route in Medicare explicitly targeting multi-cancer early detection technologies: it both opens a reimbursement channel and prescribes how CMS must approach coverage and payment. The statutory payment benchmark and age/frequency limits will shape early market adoption, evidence-generation plans by manufacturers, and potential downstream utilization of diagnostic services.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The core change in the bill is a new, statutory category for 'multi-cancer early detection screening tests' inserted into Medicare's definitions. To qualify, a test must be furnished on or after January 1, 2028; have an FDA authorization pathway (510(k), 513(f)(2) classification, or premarket approval under section 515); and be either a genomic sequencing blood or blood-product test that analyzes cell‑free nucleic acids or a sample-based test that the Secretary finds comparable.
CMS must determine that a given test is reasonable and necessary for prevention or early detection and appropriate for Medicare beneficiaries by using the established national coverage determination (NCD) process.
On payment, the bill creates a temporary pricing mechanism: for tests furnished before January 1, 2031, payment is set equal to whatever payment rate exists on enactment for the multi-target stool DNA test. For tests furnished on or after January 1, 2031, payment is the lesser of that stool-DNA‑linked amount or the payment amount CMS determines under section 1834A.
The statute also bars payment if the beneficiary has already received a test within the previous 11 months and establishes an age-based cutoff that starts at 68 in 2028 and increases by one year each subsequent calendar year — meaning beneficiaries at or above that age on January 1 of a year are ineligible for payment that year under this provision.The bill contains a carve-out tied to clinical guidance: if a multi-cancer test receives an A or B recommendation from the U.S. Preventive Services Task Force and coverage is provided under the preventive-services coverage provision referenced in the bill, the payment and limitation rules in the new payment subsection do not apply. The text also includes a rule of construction clarifying that coverage of these tests does not displace existing Medicare coverage for organ‑specific screening tests (breast, cervical, colorectal, lung, prostate) nor prevent multi-cancer tests from being used diagnostically or as confirmatory testing following another screening.
The Five Things You Need to Know
The statutory definition conditions Medicare coverage on FDA authorization via 510(k), a 513(f)(2) classification, or a PMA under section 515 — tests without those clearances must go through CMS's NCD evidence process to be considered.
For tests furnished before Jan 1, 2031, Medicare payment is pegged to the payment amount that applies to the multi-target stool DNA screening test as of enactment; after Jan 1, 2031, payment is the lesser of that stool‑DNA amount or the rate set under section 1834A.
The bill prohibits Medicare payment for a multi-cancer test if the individual received such a test within the prior 11 months, effectively limiting coverage to roughly an annual interval or longer.
The statute establishes a rolling age cutoff: no payment during a year if, as of January 1 that year, the beneficiary has attained the statutory age (68 in 2028, increasing by one year each calendar year thereafter).
If the USPSTF assigns an A or B grade to a test and it is covered under the preventive‑services statutory citation invoked, the bill exempts that test from the new subsection’s payment and limitation rules.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Designates the act as the 'Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act.' This is purely nominal but is how the statute will be cited in administrative and legal references.
New Medicare benefit category and definition
Adds a new subparagraph to Medicare definitions enumerating 'multi-cancer early detection screening tests' and inserts a new subsection (nnn) that sets out the statutory definition. The definition ties coverage eligibility to three elements: (1) date of service on or after Jan 1, 2028; (2) an FDA clearance/approval pathway (510(k), 513(f)(2), or PMA); and (3) test type (primarily genomic blood tests analyzing cell‑free nucleic acids, or other sample-based tests the Secretary deems comparable). It also mandates that CMS apply the national coverage determination (NCD) process when evaluating whether a test satisfies Medicare's 'reasonable and necessary' standard for coverage.
Payment benchmark, transition, and utilization limits
Creates a new payment subsection that sets an interim payment equal to the payment amount in effect for multi-target stool DNA tests through 2030, and then requires that, beginning Jan 1, 2031, the payment be the lesser of that interim amount or the amount CMS sets under section 1834A. The subsection also adds two utilization restrictions: an annual-use rule (no payment if the individual received a test within the previous 11 months) and an age-based exclusion tied to a specified age that starts at 68 in 2028 and rises by one year each subsequent year. Finally, it states that these payment and limitation rules do not apply to tests that receive a USPSTF A or B grade and are covered under the preventive-services coverage pathway referenced in the statute.
Cross-reference and noncoverage language
Makes technical adjustments to cross-references in sections 1833 and 1834 to include the new payment subsection, and amends section 1862(a) (the exclusions from Medicare payment) to add a specific noncoverage clause for multi-cancer tests that are not determined to be reasonable and necessary for concurrent detection across organ sites. These amendments align existing payment and benefit-exclusion language with the new test category.
Non-displacement of existing cancer screening coverage
Clarifies that the creation of this benefit category does not change Medicare coverage for existing organ-specific screening tests (for example, breast, cervical, colorectal, lung, or prostate cancer), nor does it prevent multi-cancer tests from being used as diagnostic or confirmatory tests following another screening. This reduces legal ambiguity about overlapping screening pathways and preserves existing preventive benefits.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Medicare beneficiaries under the statutory age cutoff: beneficiaries who are below the age threshold for a given year gain explicit Medicare coverage access for qualifying multi-cancer early-detection tests, potentially improving early diagnosis opportunities.
- Test developers and manufacturers of cfDNA and genomic sequencing assays: the bill creates a defined reimbursement pathway and an interim pricing benchmark, increasing the commercial viability of bringing such tests to market for the Medicare population.
- Clinical laboratories and diagnostic service providers: laboratories that perform covered tests obtain a clearer route to bill Medicare for services that otherwise might have faced coverage uncertainty, supporting scale-up of testing capacity.
- Oncology and primary-care practices prepared to manage follow-up: clinicians who establish diagnostic and referral pathways for positive screening results can expect demand for confirmatory diagnostics and care coordination to increase.
- Public health and researchers: the statutory requirement to use the NCD process encourages generation and submission of evidence to CMS, which may improve the evidence base for population-level screening over time.
Who Bears the Cost
- Medicare Trust Funds / CMS: expanding coverage and establishing payment will increase Medicare program exposure to the costs of widespread screening and to downstream diagnostic and treatment services triggered by positive findings.
- Manufacturers and test sponsors: although the bill creates reimbursement opportunity, sponsors must secure appropriate FDA authorizations and prepare the evidentiary package for the NCD process, which requires time and investment.
- Medicare administrative contractors and CMS operations: implementing new benefit rules, payment codes, eligibility checks tied to the rolling age cutoff, and enrollment/claims edits for the 11‑month interval will impose administrative and IT costs.
- Specialty diagnostic services and hospitals: an increase in screening may lead to more follow-up imaging, biopsies, and specialist visits, shifting costs and capacity burdens onto downstream care providers.
- Beneficiaries who exceed the age cutoff: older Medicare beneficiaries who are at or above the annual age threshold may be excluded from payment under this provision, producing potential access and equity concerns for that group.
Key Issues
The Core Tension
The bill squarely faces the trade-off between expanding access to promising early-detection technologies and protecting Medicare finances and beneficiaries from unproven screening that may generate false positives and downstream costs: it creates a reimbursement pathway to encourage uptake, but attaches payment caps, eligibility limits, and an evidence-review requirement that can both slow adoption and limit access — a policy tension with no clean technical resolution.
The bill mixes a pro-access approach (creating a coverage pathway) with tight cost‑ and utilization controls (an interim payment benchmark, a rolling age cutoff, and an 11‑month interval). That hybrid creates operational and policy tensions.
First, using the NCD process ties coverage to evidence generation — an appropriate safeguard — yet the statute also prescribes payment terms in advance of NCD conclusions. CMS may be boxed into reimbursing at a statutorily defined level for some period even while an evidence review is underway, or conversely could withhold coverage pending NCD outcomes; the law does not resolve how CMS should reconcile interim payment with a negative NCD.
Second, the age‑based, year-by-year cutoff is mechanically unusual and raises equity and cohort‑effect questions. A beneficiary aged 68 on Jan 1, 2028, is excluded for that year while someone a year younger is eligible, and the cutoff moves upward annually; the statute does not explain the public‑health rationale for this phasing or how it interacts with age-related cancer risk.
Third, the 11‑month frequency limit and the payment cap tied to a stool-DNA test rate may unduly constrain clinical use or conversely prove insufficient to cover the true cost of complex sequencing assays, affecting market entry incentives and potentially driving private payers' decisions.
Finally, clinical uncertainty remains significant for multi‑cancer early detection technology: many tests detect signals without established tumor‑site localization or demonstrated mortality benefit. The bill preserves diagnostic flexibility, but it does not address downstream coverage explicitly (for example, whether diagnostic imaging or invasive follow-up triggered by a screen will be reimbursed in all circumstances), leaving implementation gaps that could generate disputes or access barriers.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.